Trimetazidine dihydrochloride

Trimetazidine dihydrochloride, also known as Vastarel F or commercialized as Trimetazidine Dihydrochloride Tablets (e.g., Wanshuangli), exhibits a range of pharmacological properties and efficacies. 

1. Anti-anginal Effect:

   • Trimetazidine dihydrochloride is an effective anti-anginal agent. It works by inhibiting fatty acid β-oxidation and shifting energy metabolism towards glucose oxidation, which helps to improve myocardial glucose utilization.
   • This shift preserves ATP levels and maintains the normal function of ion pumps and transmembrane sodium-potassium flows, thereby stabilizing the intracellular environment.
   • By protecting cellular energy metabolism under hypoxic or ischemic conditions, it reduces the frequency of angina pectoris attacks.

2. Cytoprotective and Anti-ischemic Properties:

   • As a cytoprotective anti-ischemic agent, Trimetazidine dihydrochloride helps maintain the energy metabolism of the heart and neurosensory organs during ischemia and hypoxia.
   • It reduces intracellular acidosis and alters transmembrane ion flow caused by ischemia.

3. Vasodilatory and Anti-inflammatory Effects:

   • Trimetazidine dihydrochloride also acts as a vasodilator in ischemic heart disease, improving blood flow to the heart and reducing the workload on the myocardium.
   • It possesses antioxidant and anti-inflammatory properties, which may contribute to its cardioprotective effects by reducing oxidative stress and inflammation in the cardiovascular system.

4. Improvement of Myocardial Function:

   • Animal studies have shown that Trimetazidine dihydrochloride can reduce the size of myocardial infarction and improve myocardial function under hypoxic conditions.
   • It enhances the viability of injured cells, such as human umbilical vein endothelial cells (HUVECs), induced by oxidation.

5. Adjuvant Therapy for Other Conditions:

   • In addition to its primary cardiovascular effects, Trimetazidine dihydrochloride may also be used as adjuvant therapy for conditions such as pulmonary artery hypertension, although further clinical research is needed to confirm its efficacy in these areas.

Trimetazidine dihydrochloride has multiple uses, primarily in the treatment of cardiovascular diseases. 

1. Anti-anginal Agent:
   • Trimetazidine dihydrochloride is widely used as an anti-anginal agent. It acts by optimizing myocardial energy metabolism, thereby reducing the frequency of angina pectoris attacks. This makes it a valuable treatment option for patients with stable angina pectoris.
2. Cardioprotection:
   • The drug provides cardioprotection by preserving myocardial cells under ischemic or hypoxic conditions. It achieves this by inhibiting fatty acid β-oxidation and shifting energy metabolism towards glucose oxidation, which helps maintain ATP levels and normal ion pump function.
3. Improvement of Myocardial Function:
   • Trimetazidine dihydrochloride has been shown to improve myocardial function, particularly in patients with ischemic heart disease. It can reduce the size of myocardial infarction and enhance the viability of injured myocardial cells.
4. Adjuvant Therapy:
   • In addition to its primary uses, Trimetazidine dihydrochloride may also be used as adjuvant therapy in combination with other drugs for the treatment of cardiovascular diseases. Its ability to improve myocardial energy metabolism and protect myocardial cells makes it a useful adjunct in the management of these conditions.
5. Other Potential Uses:
   • Although not primarily indicated for these purposes, Trimetazidine dihydrochloride may also have potential applications in the treatment of other conditions such as pulmonary artery hypertension, based on its vasodilatory and anti-inflammatory properties. However, further clinical research is needed to confirm these potential uses.